Ingested interferon α suppresses Type I diabetes in non-obese diabetic mice

S. A. Brod, M. Malone, S. Darcan, Miguel Pappolla, L. Nelson

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Type I diabetes mellitus is a chronic disorder that results from autoimmune destruction of the insulin-producing pancreatic beta cell. The non-obese diabetic mouse is a model of the human autoimmune disease Type I diabetes [1-3]. We have previously shown that ingested type 1 interferon inhibits chronic relapsing experimental autoimmune encephalomyelitis and the adoptive transfer of experimental autoimmune encephalomyelites by T cells, and decreases both antigen-specific and mitogen-induced pro-inflammatory cytokine secretion in this disorder. We therefore tried to determine whether ingested murine interferon α inhibits insulinitis and suppresses Type I diabetes mellitus in non-obese diabetic mice. Murine interferon α, given daily, decreased islet inflammation and suppressed diabetes. It increased the concanavalin A and ionomycin plus myristic acid palmitic ester-induced production of interleukin 4 and 10 and interferon γ-secretion in spleen cells from treated mice. Adoptive transfer of unstimulated splenocytes secreting interleukin 4 and interleukin 10 from fed interferon α donors suppressed spontaneous diabetes mellitus in recipients. The protective effect of adoptively transferred unstimulated splenocytes shows the presence of ingested interferon α-activated regulatory splenic cell populations that may work via increased interleukin 4 or interleukin 10 production. Ingested interferon α administered during vulnerable periods in at-risk populations may potentially provide a continuous, convenient, non-toxic and effective treatment for Type I diabetes.

Original languageEnglish (US)
Pages (from-to)1227-1232
Number of pages6
JournalDiabetologia
Volume41
Issue number10
DOIs
StatePublished - 1998
Externally publishedYes

Fingerprint

Inbred NOD Mouse
Type 1 Diabetes Mellitus
Interferons
Interleukin-4
Interleukin-10
Adoptive Transfer
Interferon Type I
Ionomycin
Autoimmune Experimental Encephalomyelitis
Myristic Acid
Insulin-Secreting Cells
Concanavalin A
Mitogens
Autoimmune Diseases
Diabetes Mellitus
Esters
Spleen
Insulin
Cytokines
Inflammation

Keywords

  • Adoptive transfer
  • Ingested interferon α
  • Interleukin 10
  • Interleukin 4
  • Non-obese diabetic mouse

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Ingested interferon α suppresses Type I diabetes in non-obese diabetic mice. / Brod, S. A.; Malone, M.; Darcan, S.; Pappolla, Miguel; Nelson, L.

In: Diabetologia, Vol. 41, No. 10, 1998, p. 1227-1232.

Research output: Contribution to journalArticle

Brod, S. A. ; Malone, M. ; Darcan, S. ; Pappolla, Miguel ; Nelson, L. / Ingested interferon α suppresses Type I diabetes in non-obese diabetic mice. In: Diabetologia. 1998 ; Vol. 41, No. 10. pp. 1227-1232.
@article{8861d1e1b1ff4fd880f5b4063722dbbd,
title = "Ingested interferon α suppresses Type I diabetes in non-obese diabetic mice",
abstract = "Type I diabetes mellitus is a chronic disorder that results from autoimmune destruction of the insulin-producing pancreatic beta cell. The non-obese diabetic mouse is a model of the human autoimmune disease Type I diabetes [1-3]. We have previously shown that ingested type 1 interferon inhibits chronic relapsing experimental autoimmune encephalomyelitis and the adoptive transfer of experimental autoimmune encephalomyelites by T cells, and decreases both antigen-specific and mitogen-induced pro-inflammatory cytokine secretion in this disorder. We therefore tried to determine whether ingested murine interferon α inhibits insulinitis and suppresses Type I diabetes mellitus in non-obese diabetic mice. Murine interferon α, given daily, decreased islet inflammation and suppressed diabetes. It increased the concanavalin A and ionomycin plus myristic acid palmitic ester-induced production of interleukin 4 and 10 and interferon γ-secretion in spleen cells from treated mice. Adoptive transfer of unstimulated splenocytes secreting interleukin 4 and interleukin 10 from fed interferon α donors suppressed spontaneous diabetes mellitus in recipients. The protective effect of adoptively transferred unstimulated splenocytes shows the presence of ingested interferon α-activated regulatory splenic cell populations that may work via increased interleukin 4 or interleukin 10 production. Ingested interferon α administered during vulnerable periods in at-risk populations may potentially provide a continuous, convenient, non-toxic and effective treatment for Type I diabetes.",
keywords = "Adoptive transfer, Ingested interferon α, Interleukin 10, Interleukin 4, Non-obese diabetic mouse",
author = "Brod, {S. A.} and M. Malone and S. Darcan and Miguel Pappolla and L. Nelson",
year = "1998",
doi = "10.1007/s001250051056",
language = "English (US)",
volume = "41",
pages = "1227--1232",
journal = "Diabetologia",
issn = "0012-186X",
publisher = "Springer Verlag",
number = "10",

}

TY - JOUR

T1 - Ingested interferon α suppresses Type I diabetes in non-obese diabetic mice

AU - Brod, S. A.

AU - Malone, M.

AU - Darcan, S.

AU - Pappolla, Miguel

AU - Nelson, L.

PY - 1998

Y1 - 1998

N2 - Type I diabetes mellitus is a chronic disorder that results from autoimmune destruction of the insulin-producing pancreatic beta cell. The non-obese diabetic mouse is a model of the human autoimmune disease Type I diabetes [1-3]. We have previously shown that ingested type 1 interferon inhibits chronic relapsing experimental autoimmune encephalomyelitis and the adoptive transfer of experimental autoimmune encephalomyelites by T cells, and decreases both antigen-specific and mitogen-induced pro-inflammatory cytokine secretion in this disorder. We therefore tried to determine whether ingested murine interferon α inhibits insulinitis and suppresses Type I diabetes mellitus in non-obese diabetic mice. Murine interferon α, given daily, decreased islet inflammation and suppressed diabetes. It increased the concanavalin A and ionomycin plus myristic acid palmitic ester-induced production of interleukin 4 and 10 and interferon γ-secretion in spleen cells from treated mice. Adoptive transfer of unstimulated splenocytes secreting interleukin 4 and interleukin 10 from fed interferon α donors suppressed spontaneous diabetes mellitus in recipients. The protective effect of adoptively transferred unstimulated splenocytes shows the presence of ingested interferon α-activated regulatory splenic cell populations that may work via increased interleukin 4 or interleukin 10 production. Ingested interferon α administered during vulnerable periods in at-risk populations may potentially provide a continuous, convenient, non-toxic and effective treatment for Type I diabetes.

AB - Type I diabetes mellitus is a chronic disorder that results from autoimmune destruction of the insulin-producing pancreatic beta cell. The non-obese diabetic mouse is a model of the human autoimmune disease Type I diabetes [1-3]. We have previously shown that ingested type 1 interferon inhibits chronic relapsing experimental autoimmune encephalomyelitis and the adoptive transfer of experimental autoimmune encephalomyelites by T cells, and decreases both antigen-specific and mitogen-induced pro-inflammatory cytokine secretion in this disorder. We therefore tried to determine whether ingested murine interferon α inhibits insulinitis and suppresses Type I diabetes mellitus in non-obese diabetic mice. Murine interferon α, given daily, decreased islet inflammation and suppressed diabetes. It increased the concanavalin A and ionomycin plus myristic acid palmitic ester-induced production of interleukin 4 and 10 and interferon γ-secretion in spleen cells from treated mice. Adoptive transfer of unstimulated splenocytes secreting interleukin 4 and interleukin 10 from fed interferon α donors suppressed spontaneous diabetes mellitus in recipients. The protective effect of adoptively transferred unstimulated splenocytes shows the presence of ingested interferon α-activated regulatory splenic cell populations that may work via increased interleukin 4 or interleukin 10 production. Ingested interferon α administered during vulnerable periods in at-risk populations may potentially provide a continuous, convenient, non-toxic and effective treatment for Type I diabetes.

KW - Adoptive transfer

KW - Ingested interferon α

KW - Interleukin 10

KW - Interleukin 4

KW - Non-obese diabetic mouse

UR - http://www.scopus.com/inward/record.url?scp=0031782993&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031782993&partnerID=8YFLogxK

U2 - 10.1007/s001250051056

DO - 10.1007/s001250051056

M3 - Article

C2 - 9794112

AN - SCOPUS:0031782993

VL - 41

SP - 1227

EP - 1232

JO - Diabetologia

JF - Diabetologia

SN - 0012-186X

IS - 10

ER -